Fact-checked by Grok 2 weeks ago

CBD

Cannabidiol (CBD) is a naturally occurring, non-psychoactive phytocannabinoid compound primarily extracted from Cannabis sativa plants, including varieties classified as hemp, distinguished from tetrahydrocannabinol (THC) by its lack of intoxicating effects on the central nervous system.^[1] ^[2] CBD interacts indirectly with the endocannabinoid system through modulation of various receptors and enzymes, exhibiting anti-inflammatory, antioxidant, and neuroprotective properties in preclinical models, though its precise mechanisms remain under investigation.^[2] First isolated in pure form in the 1960s following its discovery in the 1940s, CBD gained prominence after the U.S. Food and Drug Administration (FDA) approved Epidiolex, a purified oral solution containing CBD, in 2018 for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients aged one year and older, marking the first cannabis-derived drug approved for a rare pediatric epilepsy indication based on randomized controlled trials demonstrating significant seizure reduction.^[3] ^[4] Despite this targeted approval, CBD's broader therapeutic applications—such as for anxiety, chronic pain, insomnia, and inflammation—lack robust empirical support from large-scale, high-quality clinical trials, with multiple systematic reviews and meta-analyses from 2023–2025 concluding no superior efficacy over placebo for pain relief and highlighting potential risks including elevated liver enzymes, drug interactions, and gastrointestinal side effects at higher doses.^[5] ^[6] ^[7] Over-the-counter CBD products, legalized federally in the U.S. under the 2018 Farm Bill for hemp-derived items containing less than 0.3% THC, proliferate in unregulated markets with inconsistent dosing, purity, and labeling accuracy, fueling controversies over unsubstantiated health claims that violate FDA guidelines against implying disease treatment without evidence.^[3] ^[8] Preliminary evidence suggests anxiolytic potential in specific contexts like social anxiety disorder, but causal links to widespread benefits are weakened by small sample sizes, heterogeneity in formulations, and pharmacokinetic variability influenced by factors such as hepatic impairment.^[9] ^[10] These limitations underscore ongoing debates regarding CBD's risk-benefit profile, with peer-reviewed data emphasizing the need for further rigorous studies to distinguish hype from verifiable outcomes amid commercial pressures.^[11]

Cannabidiol

History and discovery

Cannabidiol (CBD) was first isolated in pure form in 1940 by American chemist Roger Adams at the University of Illinois from Cannabis sativa plant material.^[12] This initial extraction laid the groundwork for identifying CBD as a distinct non-psychoactive constituent of cannabis, distinct from earlier isolations of cannabinol in the 1930s and 1940s by Adams and others.^[12] ^[13] The full chemical structure of CBD was elucidated in 1963 by Raphael Mechoulam and Yechiel Gaoni at the Hebrew University of Jerusalem, enabling precise synthesis and further pharmacological investigation.^[14] Mechoulam's team synthesized CBD shortly thereafter, confirming its identity and distinguishing it from delta-9-tetrahydrocannabinol (THC), which they isolated in pure form in 1964.^[14] Early pharmacological studies in the late 1960s and 1970s, including animal models, established that CBD lacked the intoxicating effects of THC and did not produce cannabis-like behavioral changes, shifting focus from psychoactivity to potential therapeutic properties.^[14] ^[15] Research on CBD waned after the 1970s due to regulatory restrictions on cannabis and emphasis on THC, but interest revived in the 2010s amid growing evidence of its non-intoxicating profile and preclinical data.^[14] The Agriculture Improvement Act of 2018 (Farm Bill), signed into law on December 20, 2018, removed hemp—defined as cannabis with ≤0.3% delta-9-THC—from the Controlled Substances Act, legalizing its cultivation and enabling expanded production and research into CBD-rich derivatives.^[16] A pivotal regulatory milestone occurred on June 25, 2018, when the FDA approved Epidiolex (purified CBD oral solution) as the first cannabis-derived drug for medical use in the U.S., specifically for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients aged 2 years and older.^[17] This approval marked CBD's transition from research compound to clinically viable pharmaceutical, predicated on randomized controlled trials demonstrating efficacy in these epilepsy forms.^[17]

Chemical structure and properties

Cannabidiol (CBD) possesses the empirical formula C₂₁H₃₀O₂ and a molecular weight of 314.45 g/mol, classifying it as a phytocannabinoid with a characteristic terpenophenolic backbone comprising a resorcinol-type phenolic ring linked to a monoterpene unit via an alkyl chain.^[18]^[19] This structure features an open cyclohexene ring and phenolic hydroxyl groups, differing from the pyran ring in Δ⁹-tetrahydrocannabinol (THC), which contributes to CBD's lack of psychoactivity through reduced affinity for cannabinoid receptor CB1.^[18]^[20] Physically, CBD appears as a colorless crystalline solid with a melting point of 62–63 °C and a boiling point of approximately 160–180 °C under reduced pressure.^[21]^[22] It exhibits low aqueous solubility (negligible in water) but high solubility in nonpolar solvents and moderate solubility in polar organic solvents like ethanol and dimethyl sulfoxide (≈23.6 mg/mL).^[22]^[23] CBD is commonly isolated from Cannabis sativa via supercritical fluid extraction using carbon dioxide (CO₂), where CO₂ is pressurized above its critical point (31.1 °C, 73.8 bar) to achieve solvent-like properties, enabling selective extraction of cannabinoids with minimal thermal degradation and high purity yields.^[24]^[25] This method outperforms solvent-based alternatives by avoiding residual chemicals and preserving terpenophenolic integrity.^[26] Chemically, CBD demonstrates instability to environmental factors, undergoing oxidative degradation and isomerization under exposure to light (particularly UV), heat, and oxygen; for instance, storage at 37–40 °C can result in up to 20% loss over 30 days, with accelerated breakdown in open containers or solutions.^[27]^[28]^[29] Photodegradation primarily affects the phenolic moieties, while thermal stress promotes cyclization or conversion to related compounds like cannabielsoin.^[30]^[31]

Pharmacology and mechanism of action

Cannabidiol (CBD) primarily modulates the endocannabinoid system (ECS) indirectly, exhibiting low affinity for canonical cannabinoid receptors CB1 and CB2, with Ki values exceeding 1 μM for both, in contrast to tetrahydrocannabinol (THC)'s high-affinity binding.^[2] Instead, CBD acts as a negative allosteric modulator at CB1 receptors, reducing the efficacy of orthosteric agonists like THC without displacing them, as demonstrated in vitro using recombinant human CB1-expressing cells.^[2] At CB2 receptors, CBD promotes indirect agonism by inhibiting the reuptake and degradation of endocannabinoids such as anandamide, thereby enhancing endogenous signaling without direct receptor activation.^[2] This non-competitive modulation underlies many of CBD's effects on inflammation and neurotransmission, distinct from THC's psychoactive profile.^[32] Beyond the ECS, CBD interacts with multiple non-cannabinoid targets, functioning as an agonist at serotonin 5-HT1A receptors (EC50 ≈ 16 nM in vitro), which contributes to anxiolytic and antidepressant-like effects via G-protein-coupled signaling that inhibits adenylate cyclase and modulates neuronal excitability.^[2] It also activates transient receptor potential vanilloid 1 (TRPV1) channels (EC50 ≈ 3.7 μM), leading to desensitization and calcium influx that influences pain perception and thermoregulation.^[32] As an antagonist at orphan G-protein-coupled receptor 55 (GPR55), CBD blocks its activation by lysophosphatidylinositol, potentially mitigating GPR55-mediated pro-inflammatory responses.^[2] Additionally, CBD serves as a partial agonist at peroxisome proliferator-activated receptor gamma (PPARγ), promoting anti-inflammatory pathways by transrepressing nuclear factor-kappa B (NF-κB) and enhancing fatty acid oxidation, as evidenced in microglial cell models.^[32] Pharmacokinetically, CBD demonstrates route-dependent bioavailability, with oral administration yielding 6-15% absorption due to extensive first-pass metabolism via cytochrome P450 enzymes (primarily CYP3A4 and CYP2C19), while sublingual or inhalational routes achieve 12-35% and up to 31%, respectively.^[33] Following absorption, CBD undergoes rapid distribution with a volume of 32-209 L/kg, exhibiting high protein binding (>94%) and tissue partitioning, particularly into adipose.^[33] Its elimination half-life averages 18-32 hours across dosing routes, reflecting biphasic kinetics with a prolonged terminal phase due to enterohepatic recirculation and slow release from fat stores, as quantified in human pharmacokinetic studies involving single and multiple doses.^[33] Metabolism produces over 100 hydroxylated and carboxylated metabolites, primarily excreted fecally (>85%) after hepatic conjugation.^[33]

Medical applications and clinical evidence

Cannabidiol (CBD) has demonstrated robust clinical efficacy in treating seizures associated with specific epilepsy syndromes, particularly through the FDA-approved formulation Epidiolex. In randomized controlled trials (RCTs) for Lennox-Gastaut syndrome (LGS), patients receiving Epidiolex (typically 20 mg/kg/day) experienced a median 41.9% reduction in drop seizures compared to 17.2% with placebo over 14 weeks, with 44% of treated patients achieving at least a 50% reduction versus 24% on placebo.^[34] Similar phase 3 trials for Dravet syndrome showed a 47% median reduction in convulsive seizures versus 27% placebo, establishing Epidiolex as the first CBD-based drug approved by the FDA in June 2018 for patients aged 2 years and older with these conditions, later expanded to tuberous sclerosis complex.^[35] These results stem from high-quality, double-blind RCTs involving hundreds of participants, underscoring CBD's antiseizure effects via modulation of neuronal excitability, though benefits are adjunctive to standard antiepileptic therapies.^[36] Evidence for CBD in other neurological and psychiatric conditions remains mixed or preliminary, often limited by small sample sizes, short durations, and high placebo responses. For anxiety disorders, including generalized and social anxiety, acute CBD dosing (300-600 mg) has shown reductions in subjective anxiety in small RCTs and a 2024 meta-analysis of nine studies (n=324), but effect sizes were modest (Hedges' g ≈ 0.5), with inconsistent replication in chronic use and calls for larger trials to address heterogeneity.^[10] In schizophrenia, RCTs and a 2021 systematic review found no significant improvements in core symptoms or cognition with CBD adjunctive to antipsychotics, despite preclinical promise; one trial noted minor positive symptom relief but was underpowered (n=43), and meta-analyses highlight insufficient evidence overall.^[37] Chronic pain applications, per a 2024 systematic review of 15 clinical studies, yielded low-quality evidence for modest analgesia in neuropathic and inflammatory pain, frequently confounded by THC co-administration or non-randomized designs, with preclinical data not translating reliably to humans.^[38] Broader "wellness" claims for CBD in sleep disturbances or general inflammation lack support from rigorous RCTs, as benefits often require THC synergy or fail to exceed placebo in isolated CBD trials, per systematic assessments emphasizing publication bias and industry-funded studies inflating perceived efficacy.^[39] Ongoing phase 2/3 trials explore CBD for post-traumatic stress disorder (PTSD), with preliminary data suggesting reduced craving and anxiety when combined with exposure therapy, but results await confirmation from larger cohorts (e.g., n=150 planned).^[40] Similarly, trials for addiction, such as alcohol use disorder comorbid with PTSD, test CBD's role in cue-elicited craving, showing tolerability but unproven superiority over placebo in interim analyses.^[41] These investigations underscore the need for long-term, adequately powered RCTs to mitigate risks of overgeneralization from underpowered or preclinical data, given CBD's variable bioavailability and interactions.^[42]

Safety profile, side effects, and risks

Cannabidiol (CBD) is generally well-tolerated in short-term clinical use at doses up to 1,500 mg/day, though adverse events occur in a dose-dependent manner.^[43] Systematic reviews of randomized controlled trials indicate that the most frequent side effects include gastrointestinal disturbances such as diarrhea (incidence up to 59.5% across studies), somnolence (16.7%), and decreased appetite (16.5%).^[44] Less common effects encompass fatigue, dry mouth, and headache, with incidences typically ranging from 8-11% in healthy adults receiving daily oral doses.^[43] CBD inhibits cytochrome P450 enzymes, particularly CYP3A4, CYP2C19, and CYP1A2, leading to pharmacokinetic interactions that elevate plasma levels of co-administered drugs metabolized by these pathways.^[45] For instance, CBD increases exposure to clobazam (used in epilepsy) by up to fivefold and warfarin (an anticoagulant) by inhibiting its metabolism, raising risks of sedation, bleeding, or toxicity.^[46] These time-dependent inhibitions necessitate caution with substrates like certain antidepressants, antiepileptics, and statins, as clinical studies confirm altered drug clearance after chronic CBD exposure.^[47] Unregulated CBD products frequently exhibit contamination and mislabeling, undermining safety claims. Analyses from 2017-2020 found THC present in 21-25% of tested samples despite zero-THC labeling, with concentrations up to 2 mg/mL exceeding legal limits in some cases.^[48] Heavy metals such as lead (detected in 42% of edibles), arsenic (28%), and mercury (37%) were identified in multiple studies, often surpassing safe thresholds due to extraction from contaminated hemp or poor manufacturing.^[49] Potency inaccuracies affected 70-74% of products, with deviations of at least 10% from labeled CBD content, increasing overdose or subtherapeutic risks.^[50] High-dose CBD (>20 mg/kg/day, as in the pharmaceutical formulation Epidiolex) is associated with hepatotoxicity, manifesting as elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in 11-30% of users.^[43] FDA labeling for Epidiolex warns of transaminase elevations, particularly when combined with valproate, with incidence rising dose-dependently after 2-4 weeks of use; rare cases progressed to drug-induced liver injury requiring discontinuation.^[51] Lower consumer doses (~400 mg/day) may still elevate enzymes in susceptible individuals, per randomized trials in healthy adults.^[52] Long-term human data on CBD safety remain limited, with most evidence from trials under 6 months. Animal studies reveal potential reproductive and developmental risks, including decreased sperm quality, disrupted ovarian cycles, and pup body weight reductions at doses of 150-250 mg/kg/day.^[53] Embryonic exposure in models induced teratogenicity and altered longevity, while chronic administration showed male reproductive toxicity trends, highlighting gaps in chronic human exposure effects beyond acute tolerability.^[54]

Legal and regulatory status

In 2017, the World Health Organization's Expert Committee on Drug Dependence reviewed cannabidiol (CBD) and concluded it lacks abuse potential or significant health risks warranting international control, recommending it not be placed under the UN drug conventions.^[55] This assessment influenced global approaches but did not impose uniform regulations, leaving frameworks to national authorities and resulting in disparate rules that often fail to address product purity or unsubstantiated efficacy claims.^[55] In the United States, the Agriculture Improvement Act of 2018 (Farm Bill) legalized the cultivation and sale of hemp-derived CBD containing no more than 0.3% delta-9-tetrahydrocannabinol (THC) on the federal level by removing hemp from the Controlled Substances Act's Schedule I.^[56] However, the Food and Drug Administration (FDA) classifies most CBD products as unapproved new drugs when marketed with therapeutic claims, with only Epidiolex—an FDA-approved CBD oral solution for certain seizure disorders—permitted for medical use.^[57] The FDA has concluded that existing frameworks for foods and supplements are inadequate for CBD, proposing new pathways to enforce safety standards amid widespread non-compliance.^[58] Enforcement intensified from 2020 to 2025, with the FDA issuing numerous warning letters to companies for false labeling, adulterated products, and unapproved disease-treatment claims, often in collaboration with the Federal Trade Commission (FTC).^[59]^[60] State laws vary, with some imposing stricter THC thresholds or requiring licensing, exacerbating regulatory gaps that permit misleading potency or purity assertions.^[61] In the European Union, CBD extracts qualify as novel foods under Regulation (EU) 2015/2283, necessitating pre-market authorization from the European Food Safety Authority (EFSA) based on safety data; as of 2025, no CBD product has received full approval, leading to market suspensions and legal uncertainty for ingestibles.^[62] Member states enforce varying THC limits—typically below 0.2% or 0.3%—and additional restrictions on forms like oils or foods, with ongoing EFSA reviews highlighting data deficiencies on long-term exposure.^[63] These hurdles underscore enforcement challenges, as unauthorized sales persist despite bans on health claims without evidence. Internationally, regulations diverge sharply: Japan permits CBD imports and sales only if THC is undetectable (below 0.001%), with 2024 amendments tightening scrutiny on non-medical products to prevent abuse, reflecting stringent domestic cannabis controls.^[64] In contrast, countries like Canada and Australia allow broader access under licensed frameworks, though all emphasize THC caps and verified sourcing. Debates on U.S. Drug Enforcement Administration (DEA) rescheduling of marijuana from Schedule I—proposed in 2024 but focused on whole-plant cannabis—have indirectly pressured CBD oversight, as industry advocates seek reduced stigma without resolving FDA's approval bottlenecks for non-pharmaceutical uses.^[65] Such gaps globally facilitate mislabeling and exaggerated claims, prompting calls for harmonized testing standards to mitigate public health risks from contaminants or inefficacy.^[59]

Commercial market and production

The global cannabidiol (CBD) market was valued at approximately USD 8.97 billion in 2024 and is projected to reach USD 38.97 billion by 2034, expanding at a compound annual growth rate (CAGR) of 15.83%.^[66] This growth is primarily propelled by rising consumer demand for non-pharmaceutical wellness products, including oils—which hold about 29% market share—followed by edibles such as gummies and topicals for localized applications.^[67] ^[68] E-commerce expansion and regulatory easing in key markets have further accelerated commercialization, though oversupply risks persist from fragmented production.^[66] Commercial production of CBD predominantly relies on extraction from industrial hemp (Cannabis sativa L. varieties with ≤0.3% THC), legalized in the United States via the 2018 Farm Bill, which spurred a rapid shift from illicit or imported sources to domestic farming.^[69] U.S. hemp acreage planted for all purposes surged from negligible levels pre-2018 to over 400,000 acres at its 2020 peak amid speculative investment, but contracted sharply thereafter due to plummeting prices, regulatory compliance costs, and market glut; by 2023, total planted area stood at 27,680 acres, with floral hemp (primarily for CBD) comprising the majority of utilization.^[70] ^[71] Globally, production centers in Europe and Asia have scaled via similar low-THC cultivars, emphasizing CO2 extraction methods for isolate purity, though yield variability from weather and genetics remains a challenge.^[69] Supply chain vulnerabilities undermine market reliability, as third-party testing frequently uncovers potency discrepancies; for instance, analyses of commercial CBD products show labeled concentrations deviating by 20-50% or more, with over 80% of samples in some surveys falling outside acceptable variance thresholds due to inconsistent extraction, degradation, or adulteration.^[72] ^[73] These issues, compounded by limited standardization in non-pharma segments, have prompted calls for enhanced traceability and GMP-compliant manufacturing, particularly as untested products—comprising up to 25% of offerings—pose economic and liability risks for producers.^[74] Emerging innovations seek to diversify production beyond hemp dependency, including biosynthetic approaches to generate CBD precursors or analogs in alternative crops; a 2025 study demonstrated engineering caraway seeds (Carum carvi) to produce CBD-like scaffolds for anti-seizure applications, potentially reducing reliance on cannabis cultivation amid volatile hemp economics.^[75] Such methods, while nascent, could stabilize supply by leveraging established agriculture, though scalability and regulatory approval for true CBD equivalence remain hurdles.^[76]

Central Business District

Definition and core characteristics

A central business district (CBD) constitutes the commercial nucleus of a city, defined by its dense aggregation of economic functions including offices, financial services, retail outlets, and corporate headquarters. This focal area emerges as the primary hub for business transactions and professional activities, often encompassing a limited geographic zone where land use prioritizes commerce over residential or industrial purposes.^[77]^[78] Rooted in urban economic theory, particularly the monocentric city model, the CBD represents a singular employment center that optimizes agglomeration economies—benefits from clustering firms and workers to reduce transaction costs and facilitate knowledge exchange—while assuming radial commuting patterns from peripheral residences. In this framework, all firms locate at the urban core due to fixed transportation costs and uniform worker productivity, yielding a high-density peak of activity at the center that diminishes outward.^[79]^[80] Distinguishing traits encompass elevated land values driven by scarcity and competitive bidding among high-revenue-generating uses, predominance of white-collar employment in sectors like finance and administration, vertical construction via skyscrapers to intensify floor space amid spatial constraints, and centrality to transportation infrastructure such as subways and rail terminals to support peak-hour influxes of commuters and visitors. These attributes underscore the CBD's role as a high-value, functionally specialized zone engineered for efficiency in capitalist urban systems.^[81]^[82]^[83]

Historical evolution

The concept of the central business district (CBD) emerged in the 19th century amid rapid industrialization and urbanization in Western cities, where commercial activities concentrated in urban cores to facilitate trade, finance, and manufacturing coordination. In the United States, cities expanded dramatically between 1880 and 1900, with population growth driven by industrial factories requiring proximate workforces; for instance, New York City's population rose from 33,131 in 1790 to 813,669 by 1860, fostering a dense core of banking and commerce.^[84]^[85] Similarly, London's City district solidified as a financial hub during the 1800s, leveraging its role in banking, stock exchanges, and insurance to become the world's economic center by the late 19th century, supported by innovations in rail and steam transport that centralized goods and capital flows.^[86]^[87] Post-World War II suburbanization posed significant challenges to traditional CBDs, particularly in the United States, as automobile access, highway construction, and rising incomes enabled population shifts to peripheral areas; by the 1950s, suburban growth accounted for much of metropolitan expansion, with rising real incomes explaining about 40% of suburbanization from 1950 to 1980.^[88]^[89] Yet CBDs like Manhattan persisted due to agglomeration benefits in high-value sectors such as finance and professional services, maintaining density despite edge-city competition; New York City's core retained its dominance, with neighborhoods near the CBD experiencing sustained economic activity even as suburbs absorbed residential growth.^[85]^[90] Global variations highlighted deliberate state-led adaptations; in Singapore, the 1971 Concept Plan initiated CBD development in the 1970s, rezoning areas like Shenton Way for high-rise offices and financial institutions to position the city-state as an Asian hub, with vertical skyline growth symbolizing ambitions amid post-independence industrialization.^[91]^[92] In the 21st century, CBDs have adapted to disruptions like remote work acceleration post-2020, prompting shifts toward mixed-use developments integrating residential, retail, and leisure to counter office vacancies; for example, conversions of underutilized office spaces into housing have gained traction in U.S. downtowns to revitalize cores, alongside investments in public spaces to enhance livability and attract hybrid workers.^[93]^[94]^[95]

Urban design and infrastructure

Urban design in central business districts (CBDs) emphasizes vertical density to accommodate high concentrations of commercial activity on limited land. Zoning regulations often permit tall buildings with floor area ratios exceeding 10:1, enabling skyscrapers that maximize usable space while adhering to height and setback limits. In New York City, the 1916 Zoning Resolution introduced bulk restrictions and setbacks, shaping Manhattan's CBD skyline by allowing structures like the Equitable Building's influence to spur reforms that balanced density with light and air access.^[96] This approach supports efficient land use, with CBDs featuring building densities far higher than peripheral areas, often exceeding 100,000 square feet per acre in core zones.^[97] Critical infrastructure underpins CBD functionality, particularly mass transit systems designed for rapid commuter influx. Subways and elevated rail enable the concentration of workers, as seen in New York City's Interborough Rapid Transit (IRT) line, which opened on October 27, 1904, and facilitated extraordinary daytime population densities in Manhattan's CBD by connecting residential boroughs to commercial cores.^[98] These systems, with capacities for hundreds of thousands of daily riders, reduce reliance on surface streets and promote resilience through redundancy, such as multiple lines converging at key nodes like Grand Central Terminal. Engineering features include deep tunneling for stability and electrification for efficiency, allowing CBDs to handle peak loads without gridlock.^[99] Post-2000 developments incorporate sustainability elements, including green building standards and pedestrian-oriented infrastructure to enhance resilience and reduce environmental impact. Many CBD high-rises achieve LEED certification through features like energy-efficient facades, rainwater harvesting, and rooftop greenery, cutting operational energy use by up to 30% compared to conventional designs.^[100] Pedestrian prioritization manifests in widened sidewalks, traffic-calmed streets, and elevated walkways, as in Singapore's CBD where covered linkways connect buildings, minimizing weather disruptions and encouraging non-motorized movement.^[101] Congestion remains a core challenge, addressed through infrastructure innovations like dynamic pricing and intelligent transport systems. London's 2003 Congestion Charge scheme, imposing a £5 daily fee on vehicles entering the CBD, reduced inbound traffic by 18% and overall congestion by 30% during charging hours, demonstrating how tolling infrastructure can redistribute flows to public transit.^[102] Similar trials in Stockholm (2006) achieved a 20% traffic drop via reversible cordon pricing, underscoring the role of electronic gantries and ANPR cameras in enforcing access while funding upgrades like bus priority lanes.^[103] These measures enhance systemic resilience by integrating real-time data analytics to predict and mitigate peak-hour bottlenecks.

Economic functions and impacts

Central business districts (CBDs) serve as primary engines of urban economic productivity through agglomeration economies, where the spatial concentration of firms, workers, and infrastructure fosters knowledge spillovers, labor market matching, and input sharing. Empirical studies indicate that such clustering yields a productivity premium for firms, with evidence from urban economics showing that denser urban cores like CBDs can enhance total factor productivity by 10-20% compared to peripheral locations, driven by face-to-face interactions and rapid information exchange in sectors such as finance and professional services.^[104]^[105] For instance, tech clusters within CBDs amplify innovation spillovers, boosting inventor productivity not only locally but across connected regions via shared technological advancements.^[106] CBDs concentrate employment, often accounting for 10-20% of metropolitan area jobs despite occupying a small land area, functioning as hubs for high-wage sectors like headquarters operations, finance, and legal services. This density generates substantial tax revenues for local governments, with downtown CBDs contributing disproportionately through property, sales, and business taxes; for example, major CBDs in cities like New York and Beijing produce revenues that support broader urban infrastructure.^[107]^[108] In turn, these districts facilitate global trade by hosting financial institutions and tech firms that enable cross-border transactions, risk management, and supply chain coordination, thereby enhancing a city's role in international commerce.^[109] The COVID-19 pandemic disrupted CBD economic functions via remote work shifts, causing office vacancy rates in central districts to peak at around 20% in 2021-2022 as hybrid models reduced daily occupancy. By 2025, however, vacancies have declined to approximately 19% in U.S. CBDs, signaling partial recovery amid stabilizing demand and adaptive repurposing of space, which underscores the enduring causal links between physical proximity in CBDs and sustained productivity gains.^[110]^[111]

Criticisms and socioeconomic challenges

Central business districts (CBDs) have faced criticism for exacerbating socioeconomic inequalities through gentrification processes that drive up housing costs and displace lower-income residents. In many U.S. cities, influxes of high-income workers and investments in CBD-adjacent areas have led to rent increases exceeding 20-30% in gentrifying neighborhoods between 2000 and 2020, pricing out original tenants reliant on affordable housing. ^[112] ^[113] Empirical studies indicate that while overall displacement rates may be low (around 2-5% annually in some cases), cultural and political displacement occurs as long-term residents are pushed to peripheral areas with inferior services. ^[114] ^[115] Traffic congestion and concentrated air pollution represent additional challenges in CBDs, where high densities of commuters amplify environmental and health burdens. Data from major urban centers show peak-hour delays in CBDs averaging 20-50% longer than citywide averages, contributing to elevated NO2 and particulate matter levels that exceed WHO guidelines by factors of 1.5-2 in core zones. ^[116] ^[117] These issues stem from reliance on radial transport networks funneling workers into limited central spaces, with empirical models linking CBD morphology to 10-15% higher congestion indices compared to dispersed urban forms. ^[118] Historical revitalization efforts in U.S. CBDs during the 1970s often faltered amid urban decay, as deindustrialization and suburban flight left central areas with vacancy rates climbing to 15-20% and failed public housing projects displacing communities without sustainable economic anchors. ^[119] ^[120] Critics argue these outcomes highlighted over-dependence on top-down interventions that neglected broader socioeconomic dynamics, resulting in prolonged blight until market-driven recoveries in the 1990s. ^[121] CBDs demonstrate heightened vulnerability to economic downturns, with office vacancy rates spiking sharply during recessions due to concentrated corporate functions. In the 2008 financial crisis, U.S. CBD vacancy rates in major metros like New York and San Francisco surged to 12-17% by 2010, outpacing suburban counterparts by 5-10 percentage points and amplifying local fiscal strains from lost property tax revenues. ^[122] ^[123] Recent data from the COVID-19 period reinforce this pattern, with CBD offices experiencing 20-30% drops in occupancy versus more resilient edge-city developments, underscoring debates on whether centralized economies, despite aggregate GDP boosts of 10-15% from agglomeration effects, impose disproportionate risks on urban cores. ^[124] ^[108]

Other Uses

Convention on Biological Diversity

The Convention on Biological Diversity is an international treaty adopted on May 22, 1992, at the United Nations Conference on Environment and Development in Rio de Janeiro, entering into force on December 29, 1993, after the 30th ratification.^[125] Its three primary objectives are the conservation of biological diversity, the sustainable use of its components, and the fair and equitable sharing of benefits arising from genetic resources.^[126] The treaty recognizes states' sovereign rights over their natural resources while promoting international cooperation to address biodiversity loss driven by habitat destruction, overexploitation, pollution, and invasive species.^[127] As of 2022, the Convention has been ratified by 196 parties, covering nearly all United Nations member states except the United States, which signed but has not ratified.^[128] Key supplementary agreements include the Cartagena Protocol on Biosafety, adopted in January 2000 and entering into force in September 2003, which establishes procedures for the safe handling, transport, and use of living modified organisms (LMOs) resulting from biotechnology, such as genetically modified crops, to protect biodiversity.^[129] The Nagoya Protocol, adopted in 2010, further operationalizes benefit-sharing by requiring prior informed consent for access to genetic resources and mutually agreed terms for benefit distribution, aiming to prevent unilateral exploitation. Implementation occurs through Conference of the Parties (COP) meetings, national biodiversity strategies, and action plans, with over 190 parties submitting such plans by 2022.^[130] The 2022 Kunming-Montreal Global Biodiversity Framework, adopted at COP15 in December 2022 after delays from the original Kunming hosting, sets four long-term goals for 2050 and 23 targets for 2030, including protecting or restoring 30% of global terrestrial and marine areas (the "30x30" goal) and reducing pollution and invasive species pressures by specified percentages.^[130] These targets emphasize integration with sectors like agriculture and finance, though they remain non-binding without enforcement mechanisms beyond reporting.^[131] Despite these structures, verifiable outcomes indicate limited success in reversing biodiversity decline, with global assessments showing accelerated species extinction rates—estimated at 100 to 1,000 times the background rate—and a 69% average drop in monitored vertebrate populations since 1970, trends persisting post-1992.^[132] Criticisms center on weak enforcement due to reliance on voluntary national actions without sanctions, leading to inconsistent implementation; for instance, only partial progress on access-and-benefit-sharing has been achieved, exacerbating sovereignty tensions where developing nations accuse multinational firms of biopiracy through uncompensated genetic resource use, despite Nagoya provisions.^[133] ^[134] Empirical data from the Convention's own Global Biodiversity Outlook reports confirm insufficient causal impact on halting loss, attributing gaps to economic incentives favoring short-term resource extraction over long-term conservation.^[132]

Chemical, biological, and defense applications

The U.S. Department of Defense established the Chemical and Biological Defense Program (CBDP) in 1994 to develop and acquire integrated systems for protecting military forces against chemical and biological threats, including detection, protection, decontamination, and medical countermeasures.^[135]^[136] The program emphasizes empirical threat mitigation, prioritizing capabilities validated through testing against known agents like sarin, VX nerve agents, and pathogens such as Bacillus anthracis, rather than speculative scenarios.^[137] Key technologies include advanced sensors for real-time detection of aerosolized biological agents and chemical vapors, such as joint chemical agent detectors deployed since the early 2000s, alongside protective ensembles like the Joint Service Lightweight Integrated Suit Technology.^[138] Medical countermeasures feature vaccines and therapeutics; for instance, the anthrax vaccine adsorbed (AVA), approved by the FDA in 1970 and mandated for certain U.S. troops since 1998, saw expanded research and stockpiling after the 2001 Amerithrax attacks, which involved letters containing weaponized anthrax spores mailed to media and political targets, resulting in 5 deaths and heightened focus on rapid-response prophylaxis.^[139]^[140] Post-2001 investments also advanced next-generation anthrax vaccines and broad-spectrum antimicrobials, with efficacy demonstrated in animal models under FDA's Animal Rule due to ethical constraints on human challenge studies.^[141] The CBDP's annual budget has consistently exceeded $1 billion, with the FY2025 request totaling $1.657 billion for research, development, testing, and evaluation, including allocations for countermeasure sustainment and threat agent production for validation.^[142] This funding supports facilities like the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick, which conducts agent-specific testing. Internationally, NATO aligns through its 2022 Chemical, Biological, Radiological, and Nuclear (CBRN) Defence Policy, which standardizes detection, protection, and recovery protocols across allies, including joint exercises and interoperability standards like Allied Medical Publication-7 for CBRN medical support.^[143]^[144] Criticisms of the CBDP center on potential over-allocation relative to biothreat realism, given the low historical incidence of large-scale biological attacks—such as the isolated 2001 anthrax mailings, which affected fewer than 20 individuals directly, versus routine infectious disease burdens.^[145]^[146] Some analysts, including those from arms control perspectives, argue that funds could yield higher causal returns if redirected toward chronic public health threats with empirically higher morbidity, as bioweapon deployment remains rare due to technical barriers like agent stability and attribution risks, despite state programs in nations like Russia and Syria.^[145]^[146] Proponents counter that preparedness deters asymmetric threats, with program efficacy evidenced by validated countermeasures rather than incident frequency alone, though mismanagement claims persist regarding diffused oversight and service-specific gaps.^[147]^[148]

References

[1]
Cannabidiol and brain function: current knowledge and future ...
Cannabidiol (CBD) is a naturally occurring non-psychoactive cannabinoid found in Cannabis sativa, commonly known as cannabis or hemp.
[2]
Cannabidiol: Pharmacology and Therapeutic Targets - PMC
This paper reviews the molecular targets, pharmacokinetics, and safety and abuse liability of CBD; additionally, the extant evidence on its potential ...
[3]
FDA Regulation of Cannabis and Cannabis-Derived Products
Jul 16, 2024 · FDA has approved Epidiolex, which contains a purified form of the drug substance CBD for the treatment of seizures associated with Lennox- ...What You Need to Know · FDA, FTC Continue Joint Effort... · Delta-8 THC
[4]
Cannabidiol (CBD) in Clinical Care - StatPearls - NCBI Bookshelf
May 7, 2024 · FDA approval of CBD for the treatment of Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous sclerosis complex has significantly improved the ...
[5]
Cannabidiol (CBD) Products for Pain: Ineffective, Expensive, and ...
Fifteen of the 16 RCTs were negative: no greater pain-relieving effect for CBD than for placebo. Meta-analyses link CBD to increased rates of serious adverse ...Missing: controversies | Show results with:controversies
[6]
CBD products don't ease pain and are potentially harmful
Mar 25, 2024 · There is no evidence that CBD products reduce chronic pain, and taking them is a waste of money and potentially harmful to health, new research finds.
[7]
Health Claims About Cannabidiol Products - NIH
These claims indicated that CBD could be used in the “diagnosis, cure, mitigation, treatment, or prevention of disease” without evidence of safety or efficacy ...
[8]
[PDF] Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns
FDA-approved product: FDA has determined that the benefits of the product outweigh the known risks for the intended use. Hemp: Cannabis plants and products with ...
[9]
Cannabidiol (CBD): What we know and what we don't - Harvard Health
Apr 4, 2024 · We need more research, but CBD is proving to be a helpful, relatively nontoxic option for managing anxiety, insomnia, and chronic pain.
[10]
Therapeutic potential of cannabidiol (CBD) in anxiety disorders
Our findings suggest that CBD has promising efficacy in treating specific anxiety symptoms (including GAD, SAD, OCD, and PTSD) in addition to standard ...Missing: controversies | Show results with:controversies
[11]
Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects ...
Sep 5, 2025 · In studies of nabiximols (THC + CBD spray), dizziness occurred in 25%, somnolence in 8%, and disorientation in 4% of patients, while 12 ...Missing: controversies | Show results with:controversies
[12]
History of cannabis and the endocannabinoid system - PMC
CBD was first isolated from marijuana in 1940, and its structure was reported in 1963. However, since CBD was not psychoactive, it was neglected and eclipsed by ...
[13]
The early history of cannabinoid research
Oct 8, 2020 · The note by Adams on the isolation of CBD was submitted to the Journal of America Chemical Society (JACS) on December 4, 1939, (Adams et al.
[14]
Cannabinoid pharmacology: the first 66 years - PMC - PubMed Central
Jan 9, 2006 · It was also in Mechoulam's laboratory, in 1965, that (±)-Δ9-THC and (±)-CBD were first synthesized, developments that were soon followed by the ...
[15]
Cannabidiol: from an inactive cannabinoid to a drug with wide ...
Mar 7, 2008 · Only a few pharmacological studies on CBD were reported before the early 1970's, showing that CBD had no cannabis-like activity.6 The number ...
[16]
Hemp Production and the 2018 Farm Bill - 07/25/2019 - FDA
Jul 25, 2019 · It has only been seven months since the 2018 Farm Bill removed hemp, which includes low- THC derivatives of cannabis, such as CBD products, from ...
[17]
[PDF] Approval Letter for NDA 210365 - accessdata.fda.gov
Jun 25, 2018 · Please refer to your New Drug Application (NDA), dated and received October 27, 2018, and your amendments, submitted under section 505(b) of ...
[18]
Cannabidiol | C21H30O2 | CID 644019 - PubChem - NIH
Cannabidiol is an cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, ...
[19]
Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis - PMC
May 8, 2021 · Cannabinoids are a group of compounds with a characteristic C21 terpenophenolic backbone. This nomenclature can be applied to parent ...
[20]
An Overview of Cannabidiol as a Multifunctional Drug - MDPI
Structurally, there is a critical difference between CBD and Δ9-THC: whereas the latter contains a cyclic ring, CBD includes a hydroxyl group (Figure 1).<|control11|><|separator|>
[21]
CANNABIDIOL | 13956-29-1 - ChemicalBook
Aug 20, 2025 · CANNABIDIOL Properties: Melting point 62-63°C, alpha D27 -125° (0.066 g in 5 ml 95% ethanol); D18 -129° (c = 0.45 in ethanol), Boiling point
[22]
[PDF] CANNABIDIOL (CBD) Critical Review Report
Chemical Properties. Melting point: 62-63°C. Solubility: approx. 23.6 mg/mL in DSMO and ethanol [14]. F. Identification and Analysis. There are a number of ...
[23]
The Solubility and Stability Profiles of Cannabidiol - CBD World News
Jun 12, 2020 · Generally, cannabinoids are negligibly soluble in water but are highly soluble in lipids and accumulate abundantly in the body's fatty tissues.
[24]
Utilisation of Design of Experiments Approach to Optimise ... - Nature
Jun 4, 2020 · Carbon dioxide supercritical fluid extraction (CO2 SFE) is a clean and cost-effective method of extracting cannabinoids from cannabis.
[25]
Supercritical Carbon Dioxide Technology for Recovering Valuable ...
The supercritical CO2 extraction principle is based on the contact of CO2 at supercritical conditions and the raw material, which is placed into an extraction ...
[26]
Supercritical CO2 Extraction: Equipment, Process, and Benefits
Aug 22, 2024 · Supercritical CO2 extraction uses pressurized, heated CO2 to extract compounds from cannabis, acting as a solvent with high density and low ...Supercritical CO2 Extraction vs... · Equipment and Technologies...
[27]
Stability Study of Cannabidiol in the Form of Solid Powder and ... - NIH
Mar 19, 2021 · Very significant degradation of CBD took place between the 90th and 180th day in the case of CBD oil samples in open vials at 40 °C ± 2 °C/75% ...
[28]
Quantification of the content of cannabidiol in commercially ... - Nature
Feb 28, 2020 · Stability tests showed a maximum degradation of CBD when samples were stored at 37 °C for 30 days with average values up to 20%. The effect ...
[29]
Characterizing the degradation of cannabidiol in an e-liquid ... - Nature
Nov 21, 2022 · CBD in an e-liquid formulation was found to be susceptible to heat and light exposure, with up to 20% reduction occurring after 30 days at 37 °C ...<|separator|>
[30]
Photodegradation of cannabidiol (CBD) and Δ 9 -THC in cannabis ...
May 13, 2024 · Exposure to light appears to be the key factor in the degradation of Δ9-THC, a hypothesis confirmed by more recent studies [24, 25]; the same ...
[31]
Effect of temperature in the degradation of cannabinoids - Frontiers
Oct 31, 2022 · For many years, different researchers have referred to the degradation of cannabinoids due to elevated temperatures (Czégény et al., 2021), and ...
[32]
Molecular and Cellular Mechanisms of Action of Cannabidiol - PMC
CBD exerts a wide spectrum of effects at a molecular, cellular, and organ level, affecting inflammation, oxidative damage, cell survival, pain, vasodilation, ...
[33]
A Systematic Review on the Pharmacokinetics of Cannabidiol ... - NIH
Nov 26, 2018 · The half-life of cannabidiol was reported between 1.4 and 10.9 h after oromucosal spray, 2–5 days after chronic oral administration, 24 h after ...
[34]
[PDF] EPIDIOLEX® (cannabidiol) oral solution - accessdata.fda.gov
EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in ...
[35]
FDA approves Epidiolex for Lennox-Gastaut syndrome and Dravet ...
Jun 25, 2018 · ... trials. These trials showed a 50% reduction of drop seizure frequency in 40%-44% of patients with Lennox-Gastaut syndrome, and a 39 ...
[36]
Emerging Use of Epidiolex (Cannabidiol) in Epilepsy - PMC
... Epidiolex, was approved in the United States by the FDA on June 25, 2018. Its approval for patients ≥ 2 years of age with Dravet syndrome (DS) or Lennox ...
[37]
The Impact of THC and CBD in Schizophrenia: A Systematic Review
Jul 23, 2021 · There is insufficient evidence for an effect of THC or CBD on symptoms, cognition, and neuroimaging measures of brain function in schizophrenia.
[38]
Cannabidiol (CBD): A Systematic Review of Clinical and ... - MDPI
Oct 28, 2024 · CBD has a wide pharmacological activity from anticonvulsant, anti-inflammatory, and antioxidant to antipsychotic effects. In addition, it has ...
[39]
[PDF] Living Systematic Review on Cannabis and Other Plant-Based ...
This is the fourth and final annual update of a living systematic review addressing the effectiveness and harms of plant-based treatments for chronic and ...
[40]
Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder
Participants (n=150) meeting full DSM-5 criteria for post-traumatic stress disorder (PTSD) will be randomized to one of 3 treatment arms: (a) CBD -Isolate; (b) ...Missing: addiction | Show results with:addiction
[41]
https://clinicaltrials.gov/study/NCT03248167
[42]
A phase III multisite randomised controlled trial to compare the ...
Mar 4, 2024 · This study examines the efficacy, safety and quality of life of longer-term CBD treatment for patients with moderate-to-severe CUD.
[43]
Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults
Jul 7, 2025 · In a systematic review of clinical trials initiating daily CBD treatment, 25% or 32 of 128 cases of liver enzyme level elevations resolved ...
[44]
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review ...
Nov 25, 2022 · The most common AEs (≥10% incidence) included gastrointestinal symptoms (59.5%), somnolence (16.7%), loss of appetite (16.5%), increased ALT/AST ...
[45]
Cannabinoid Interactions with Cytochrome P450 Drug Metabolism
Jun 28, 2021 · Both cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC), major constituents of cannabis, potently inhibit CYPs.
[46]
Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug ...
Jun 14, 2023 · Because CBD is usually taken chronically and is a time-dependent inhibitor of CYP2C19, CYP3A, and CYP1A2, CBD-probe drug interactions after ...
[47]
CBD-Drug Interactions: Role of Cytochrome P450 | Project CBD
Sep 8, 2015 · CBD and other plant cannabinoids can potentially interact with many pharmaceuticals by inhibiting the activity of cytochrome P450, a family of liver enzymes.
[48]
Medical Fraud, Mislabeling, Contamination: All Common in CBD ...
Of 84 samples tested, THC was detected in 21%. There were other defects in the mislabeled products. Only 30.95% were accurately labeled. Accuracy of labeling ...
[49]
Heavy metal and phthalate contamination and labeling integrity in a ...
Dec 10, 2022 · Lead was detected in 42 %, cadmium in 8 %, arsenic in 28 %, and mercury in 37 % of 121 edible CBD products. Four edible CBD products exceeded ...Missing: mislabeling | Show results with:mislabeling
[50]
Product labeling accuracy and contamination analysis of ... - NIH
Mar 18, 2024 · The majority of products (74%) deviated from their label claim of CBD potency by at least 10%. Heavy metals were detected 52 times across 44 of ...
[51]
[PDF] EPIDIOLEX® (cannabidiol) oral solution - accessdata.fda.gov
Hepatocellular Injury: EPIDIOLEX can cause transaminase elevations. Concomitant use of valproate and higher doses of EPIDIOLEX increase the risk of transaminase ...
[52]
FDA study links high consumer CBD doses to liver enzyme elevations
Jul 10, 2025 · FDA researchers report that the upper end of reported consumer use (~400mg of daily CBD intake) of cannabidiol (CBD) may elevate liver enzymes in healthy ...
[53]
Review of the oral toxicity of cannabidiol (CBD) - ScienceDirect.com
... CBD can result in developmental and reproductive toxicity and hepatotoxicity outcomes in animal models. The trend of CBD-induced male reproductive toxicity ...
[54]
Developmental exposure to cannabidiol (CBD) alters longevity and ...
Previous research in our laboratory established that embryonic exposure to high doses of CBD (≥ 2 μM) caused larval developmental teratogenicity, and altered ...
[55]
Drugs (psychoactive): Cannabidiol (compound of cannabis)
Dec 19, 2017 · WHO officially recommended on December 14, 2017 that cannabis compound cannabidiol (CBD) not be internationally scheduled as a controlled substance.
[56]
H.R.5485 - 115th Congress (2017-2018): Hemp Farming Act of 2018
This bill legalizes industrial hemp that has a tetrahydrocannabinol (THC, the psychoactive component of marijuana) concentration of no more than 0.3%.
[57]
CDER Investigators Address the Safety of CBD in a Randomized Trial
Aug 25, 2025 · CDER researchers conducted a randomized, double-blinded, placebo-controlled study in healthy participants to evaluate the effects of daily CBD ...
[58]
FDA Concludes that Existing Regulatory Frameworks for Foods and ...
Jan 26, 2023 · A new regulatory pathway would benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products.
[59]
Warning Letters for Cannabis-Derived Products - FDA
Sep 3, 2025 · This page lists FDA warning letters for firms marketing cannabis-derived products, including CBD and delta-8 THC, to protect the public.
[60]
FTC Announces Crackdown on Deceptively Marketed CBD Products
Dec 17, 2020 · The FTC is taking action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims ...Missing: labeling | Show results with:labeling<|separator|>
[61]
About CBD | Cannabis and Public Health - CDC
Jan 31, 2025 · Additionally, most CBD products are not regulated by the FDA. As such, consumers should be aware that products labeled as hemp or CBD may ...
[62]
EU 2025: EFSA's Tougher Novel Food Dossier Rules Put CBD Back ...
Sep 1, 2025 · No product containing CBD extract (regardless of source) has yet been authorized for the EU market. Thousands of applications are either paused ...
[63]
Novel Food status Catalogue - European Commission's Food Safety
The new Novel Food status Catalogue is a non-binding tool that lists products of animal and plant origin, algal species, food cultures and other substances
[64]
Is CBD Legal in Japan in 2025? | Our CBD Blog - Essentia Pura
CBD products are legal in Japan if they contain no THC (below 0.001%) and are marketed as food supplements or cosmetics, not medical products.
[65]
Schedules of Controlled Substances: Rescheduling of Marijuana
May 21, 2024 · The Department of Justice (DOJ) proposes to transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA.
[66]
Cannabidiol Market Size to Reach USD 38.97 Billion by 2034
The cannabidiol market is expected to rise from USD 8.97 billion in 2024 to USD 38.97 billion by 2034, growing at a CAGR of 15.83%.
[67]
Cannabidiol Market Size And Share | Industry Report, 2030
The global cannabidiol market size was estimated at USD 9.14 billion in 2024 and is projected to reach USD 22.05 billion by 2030, growing at a CAGR of 15.8% ...
[68]
CBD Statistics - Magnet ABA
May 11, 2025 · The CBD market segment is broad, with oils constituting approximately 29.2% of the overall market share as of 2023, and gummies expected to ...
[69]
[PDF] National Hemp Report 04/17/2025
Apr 17, 2025 · Area harvested for all purposes in the open totaled 32,694 acres, up 55 percent from 2023. Floral hemp in the open: United States floral hemp ...
[70]
How Much Hemp Was Planted in 2023?
Feb 14, 2024 · Average plot sizes expanded by about a quarter, resulting in fiber plantings exceeding the 10,000 acre threshold for the first time since hemp' ...
[71]
[PDF] National Hemp Report 04/17/2024 - usda-esmis
Apr 17, 2024 · Industrial hemp in the open: Planted area for the Nation in 2023 for all utilizations totaled 27,680 acres, down 2 percent from 2022. The value ...
[72]
Leafreport Decided to Uncover Which CBD Brands are Testing, and ...
Oct 16, 2022 · ... products have met acceptable variance levels for their potency tests ... CBD–were found to have more than 95% accuracy for product potency.Missing: inaccuracies | Show results with:inaccuracies<|separator|>
[73]
Label Accuracy of Legal Oral Cannabis Oil Products in Ontario ...
Jun 5, 2024 · Research examining legal cannabis products has found high rates of label inaccuracy for THC and CBD, 2 ,3 but to our knowledge, no study has examined label ...
[74]
New Report Finds 25% Of CBD Products Are Not Tested For Purity
Jun 30, 2021 · A separate analysis by Leafreport found that 56% of pet CBD products had inaccurate label claims. Editorial StandardsReprints & Permissions.
[75]
From Caraway to Cure: Engineering CBD-like Seizure Treatments ...
Oct 15, 2025 · From Caraway to Cure: Engineering CBD-like Seizure Treatments Without Cannabis ... Caraway seeds don't contain CBD. They just contain the scaffold ...Missing: sources | Show results with:sources
[76]
https://www.marijuanamoment.net/alcohol-companies-lobby-congress-on-cannabis-drinks-newsletter-october-22-2025/
[77]
What Is a Central Business District (CBD)? | Planopedia - Planetizen
A central business district is exactly what it sounds like—the area of densely concentrated commercial activity that forms a core of economic and population ...
[78]
Central Business District | Definition, Importance & Examples
A central business district (CBD) is defined as the main area of a city or town that is devoted to commerce and business. The CBD is typically the financial ...
[79]
The validity of the monocentric city model in a polycentric age
The monocentric urban model centered on a single Central Business District (CBD) dominated urban analysis for decades and was definitively integrated into a ...
[80]
[PDF] Introduction to the monocentric Urban Model - Florian Oswald
We assume a city has one unique center, the central business district,. CBD, where all firms are. 2. The shape of the city could be circular, or a line. We will ...
[81]
Central Business District (CBD) | Characteristics, Examples, Pros ...
Oct 9, 2024 · A CBD is the central, most used, and expensive area of a city, a business hub with high land prices, and a focal point with large footfall.
[82]
Central Business District - Glossary of CRE Terms
Aug 20, 2024 · The central business district (CBD) is typically the center of business and economic activity of a city. Land use is generally more dense.
[83]
What is a Central Business District? A Comprehensive Guide
Apr 22, 2025 · Key Features of Central Business Districts · 1. High Concentration of Commercial Activities · 2. Vertical Development · 3. Transportation Hubs and ...
[84]
City Life in the Late 19th Century - Library of Congress
Between 1880 and 1900, cities in the United States grew at a dramatic rate. Owing most of their population growth to the expansion of industry.
[85]
[PDF] Urban Dynamics in New York City
City and Manhattan as a share of the U.S. population. Between. 1790 and 1860, New York City's population rose from 33,131 to 813,669. The annual rate of ...
[86]
https://www.britannica.com/place/London/Evolution-of-the-modern-city
[87]
the evolution of London's central financial district, 1690-1870
During this period London emerged as the world centre for financial, insurance, and commodity markets.
[88]
The growth of suburbia (article) - Khan Academy
The postwar exodus to the suburbs was part of a vast reorganization of power and money that affected American industry, race relations, and gender roles.
[89]
[PDF] Urbanization in the United States, 1800-2000 - Leah Platt Boustan
rising real income can explain around 40 percent of suburbanization in the post-World War II period (1950 to 1980). At the same time, construction of the ...
[90]
https://oxfordre.com/americanhistory/display/10.1093/acrefore/9780199329175.001.0001/acrefore-9780199329175-e-654
[91]
A Loveable City for All - Urban Redevelopment Authority (URA)
Since the 1970s, we have developed a comprehensive programme to identify and retain buildings and areas of significant historical, architectural and cultural ...
[92]
[PDF] The Making of a Financial Centre - Singapore - BiblioAsia
On their part, developers had to ensure that their designs adhered to the planning parameters set up by URD, such as land use zoning, development intensity and ...
[93]
Mixed Use, Public Space, and the Future of Central Business Districts
May 23, 2022 · Here are 3 considerations for reimagining the CBD to better meet residents' needs: 1. Continue investment in parks to create a healthier, more hospitable city.
[94]
Myths about converting offices into housing—and what can really ...
Apr 27, 2023 · Many are arguing that the conversion of vacant office space into housing is a key strategy for addressing these challenges and revitalizing downtowns.
[95]
How Remote Work is Influencing Urban Real Estate Markets
Jan 9, 2025 · Commercial development companies see mixed-use projects as a way to revitalize neighborhoods impacted by declining office demand. By repurposing ...
[96]
How the 1916 Zoning Law Shaped Manhattan's Central Business ...
The second – zoning – determined the city's three-dimensional form by restricting uses by district and, especially, by limiting the maximum mass of a building ...
[97]
[PDF] The Logic of Vertical Density: Tall Buildings in the 21st Century City
This paper attempts to summarize recent debates on tall buildings. It first explains the driving forces of constructing tall buildings including population ...
[98]
[PDF] TR News 242 - New York City's Subway Century: Transit's Role in ...
The subway made possible an extraordinary density of daytime worker populations in Manhattan's central business districts—the subway's capacity, speed, and.
[99]
The Impact of the IRT on New York City (Hood) - nycsubway.org
After 1904, Broadway replaced Columbus Avenue as the main business thoroughfare in the district. The most intensive development occurred near the IRT ...
[100]
The Prioritization of Sustainability Features of Buildings from ... - MDPI
Dec 4, 2023 · This study shows that, when it comes to green buildings, the environment is the most crucial factor, followed by the economy, and then the ...
[101]
Benefits of pedestrianization and warrants to pedestrianize an area
Pedestrianization of the congested street is a very effective, low-cost and sustainable solution. Other than congestion reduction, Pedestrianization has ...
[102]
Congestion Charge marks 20 years of keeping London moving ...
Feb 17, 2023 · Limited traffic entering the zone by 18 per cent during weekday charging hours · Reduced congestion by 30 per cent · Boosted bus travel in central ...
[103]
[PDF] Second Impacts Monitoring Report - London - TfL
Congestion within the charging zone has reduced by 30 percent, and the volume of traffic in the charging zone has reduced by 15 percent (vehicles with four or ...
[104]
[PDF] Agglomeration Economies: A Literature Review - Upjohn Research
Sep 25, 2020 · There are many benefits of agglomeration including increased employment, wages, and productivity.
[105]
[PDF] what makes cities more productive? agglomeration economies and ...
13. The findings of the paper suggest that, in line with the previous literature on agglomeration economies, productivity tends to increase with city size for ...
[106]
Innovation Spillovers across U.S. Tech Clusters | NBER
Jul 11, 2024 · We show that larger tech clusters not only make local inventors more productive but also raise the productivity of inventors and plants in other clusters.
[107]
[PDF] Demographia United States Central Business Districts (Downtowns)
Total employment in the CBD and transit work trips to the CBD are scaled upward by the percentage difference between the metropolitan area total employment and ...
[108]
Assessment of economic development of central business districts
Jul 31, 2025 · The economic development of central business districts (CBDs) is a key driver of urban economic growth and enhances regional competitiveness ...
[109]
New Policies for Beijing's CBD Released, Covering Headquarters ...
Jul 23, 2024 · It focuses on advancing the headquarters economy, international finance, business district development, and attraction and utilization of foreign investment.
[110]
U.S. Office Rents Report May 2025 | CommercialEdge
May 20, 2025 · CBD office vacancy rate reached 19.2% in April, up 730 basis points since 2020, as demand continues to shift toward suburban locations; The ...
[111]
https://www.commercialcafe.com/blog/national-office-report/
[112]
Gentrification and cultural displacement in American cities
While gentrification increases the value of properties in areas that suffered from prolonged disinvestment, it also results in rising rents, home and property ...
[113]
Gentrification and retail churn: Theory and evidence - ScienceDirect
This paper presents a model in which gentrification harms incumbent residents by increasing rental costs and by eliminating distinctive local stores.
[114]
What is wrong with gentrification-related displacement?
Oct 5, 2024 · A number of theorists argue that physical displacement as a result of gentrification ought to be morally rejected on the basis of the principle of personal ...
[115]
[PDF] Contextualizing Gentrification Chaos: The Rise of the Fifth Wave1 ...
May 6, 2020 · Rather, increased rents continue to stimulate multiple forms of displacement: residential, political, and cultural (Cocola-Gant, 2019; Elliott- ...
[116]
[PDF] Traffic Congestion Problems in Central Business District (CBD) Ikeja ...
Aug 27, 2025 · This study was empirically conducted using primary and secondary data. Observation technique, aided by on spot assessment based on a 100 per ...
[117]
Pollution and congestion in urban areas: The effects of low emission ...
Overall, our empirical analysis provides evidence on the effectiveness of LEZs in abating pollution. LEZs are particularly effective in highly polluted ...
[118]
Traffic congestion and its urban scale factors: Empirical evidence ...
This study empirically investigates the causes of urban traffic congestion to bring into focus the variety of beliefs that provide support for policy ...
[119]
How to Save America's Dying Cities
Content with comfortable political monocultures, unable to abandon the same tired solutions that continue to fail to arrest the erosion of city services and a ...
[120]
[PDF] U.S. Urban Revitalization in the Twenty-First Century
After reporting on the failure of 6 percent (86,000 units) of public housing, the National Commission on Severely Distressed Housing then called for its ...
[121]
[PDF] Urban Redevelopment, Displacement and the Future of the ...
Apr 15, 1996 · The redevelopment problems that the federal urban renewal program attempted to address are identified, as are the serious failures of that ...
[122]
At 17 pct, US office vacancy rate hits 15-year high - Reuters
Jan 7, 2010 · Since the start of the recession in December 2007, the U.S. economy has shed 7.2 million jobs, drastically reducing demand for office space and ...<|separator|>
[123]
As Vacant Office Space Grows, So Does the Crisis for Lenders
Jan 4, 2009 · Vacancy rates in office buildings exceed 10 percent in virtually every major city in the country and are rising rapidly, a sign of economic ...
[124]
San Francisco office vacancy rate eclipses 2008 financial-crisis high
Jan 13, 2021 · The city's office-vacancy rate reached 16.7 per cent at the end of 2020, up 11 percentage points from a year prior, according to a report from ...
[125]
[PDF] cbd-en.pdf - Convention on Biological Diversity
The Convention entered into force on 29 December 1993, which was 90 days after the 30th ratification. The first session of the Conference of the Parties was ...
[126]
Text of the Convention
May 13, 2016 · Text of the Convention Full Text Arabic | Chinese | English | French | Russian | Spanish View the official source on the UN Treaties website.
[127]
Convention on Biodiversity | United Nations
May 22, 2025 · The Convention on Biological Diversity (CBD) is the international legal instrument for the conservation of biological diversity, the sustainable use of its ...
[128]
The Convention on Biological Diversity and Indigenous Peoples
Mar 8, 2022 · The Convention came about as a response to growing concern about the state of biodiversity ... To date, 196 parties have signed and ratified the ...<|separator|>
[129]
The Cartagena Protocol on Biosafety
An international agreement which aims to ensure the safe handling, transport and use of living modified organisms (LMOs) resulting from modern biotechnology.About the Protocol · What's new · Parties to the Cartagena... · Text
[130]
Kunming-Montreal Global Biodiversity Framework
Jan 10, 2024 · Among the Framework's key elements are 4 goals for 2050 and 23 targets for 2030. The implementation of the Kunming-Montreal Global Biodiversity ...2030 Targets (with Guidance... · Introductory sections of the GBF · 2050 Goals
[131]
Kunming-Montreal Global Biodiversity Framework | UNEP
Dec 19, 2022 · Among the twenty-three targets to be achieved by 2030 include 30 per cent conservation of land, sea and inland waters, 30 per cent restoration ...
[132]
[PDF] STATUS AND TRENDS OF GLOBAL BIODIVERSITY
The purpose of this chapter is to provide an overview of the changing status of the world's biological diversity. The first sections below.
[133]
A hard instrument goes soft: The implications of the Convention on ...
The relentless loss of biological diversity, which will have a direct impact on human society and degrade ecosystem buffers against the extremes of climate ...
[134]
S. Faizi · The unmaking of a treaty: The convention on biological ...
As a result, species after species has been misappropriated from the bio-rich South, worked on and patented, in obvious violation of the treaty. A centrepiece ...
[135]
Medical Chemical Biological Defense Research - USAMRDC
Jan 25, 2024 · The Department of Defense (DoD) established the CBDP in 1994 to provide chemical and biological defense capabilities in support of national ...
[136]
[PDF] Chemical and Biological Defense Program (CBDP) - Justification Book
Congress created the Chemical and Biological Defense Program (CBDP) to provide the Joint Force with the necessary capabilities to deter or fight through and win ...
[137]
[PDF] 2024 CBDP Enterprise Strategy
The 2024 CBDP strategy focuses on generating CBD advantages, delivering at speed and scale, optimizing the enterprise, and leveraging partnerships.
[138]
[PDF] Joint Service Chemical and Biological Defense Program (CBDP)
The CBDP focuses on the development and acquisition of an integrated system-of-systems to defend against the various chemical and biological warfare threats ...<|separator|>
[139]
Use of Anthrax Vaccine in the United States - CDC
Jul 23, 2010 · The bioterrorism events of 2001 prompted extensive biodefense research, as well as the creation and implementation of bioterrorism preparedness ...
[140]
Chemical, Biological, Radiological, and Nuclear Countermeasures
Detecting bioterrorist attacks. The anthrax attacks of October 2001 proved that quick recognition of biological terrorism is crucial to saving lives. The ...
[141]
The Department of Defense Chemical and Biological ... - PubMed
The US Department of Defense (DOD) established programs to defend against chemical and biological weapons 100 years ago because military leaders understood ...Missing: history | Show results with:history
[142]
[PDF] Chemical and Biological Defense Program (CBDP) - Justification Book
The Under Secretary of Defense for Acquisition and Sustainment has approved a new CBDP governance framework, which strengthens alignment to White House and ...
[143]
NATO's Chemical, Biological, Radiological and Nuclear (CBRN ...
Jul 5, 2022 · NATO's 2022 Chemical, Biological, Radiological and Nuclear (CBRN) Defence Policy establishes the framework upon which we will understand, plan, posture, ...
[144]
[PDF] NATO STANDARD AJMedP-7 ALLIED JOINT CHEMICAL ...
Jan 1, 2022 · This AMedP also provides an outline of the training requirement and first aid materiel for use in a CBRN environment including casualty ...
[145]
Memo to Trump: Cut the Pentagon's chemical and biological ...
Jan 17, 2025 · In 2023, the Defense Department announced the addition of $300 million to the program's annual budget to address “biological threats.
[146]
Biodefense Research Two Decades Later: Worth the Investment?
Aug 1, 2022 · Some critics of biodefense funding argue that biodefense funds would be better spent targeting chronic infectious diseases and other public ...
[147]
DoD's Mismanaged Biodefense Program - by Al Mauroni
Aug 26, 2024 · In theory, the services could object to the CBDP's misuse of funds and appeal to the Joint Requirements Oversight Council. They don't because ...Missing: overfunding | Show results with:overfunding
[148]
Biodefense Posture Review Raises Alarms about New Threats but ...
Aug 23, 2023 · There is a line of particularly harsh criticism, for a formal, public review: “the BPR revealed that DoD has a disorganized and diffused ...